Annual Report

Overview

The report describes Aurobindo Pharma's FY22 performance, combining consolidated revenue of ₹234,555 million with continued global pharmaceutical growth. Environmental highlights include 43,000 MWh of solar energy generated and consumed and a reported 5.1% renewable-energy share. The company also reports 864,836 CSR beneficiaries during the year and describes a Sustainability Framework covering responsible manufacturing, sustainable sourcing, social equity, access to healthcare, governance and CSR.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021-2022
Period: 1 April 2021 – 31 March 2022
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services